Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc., (“Arena”) executed a Second Amendment (the “Second Amendment”) to that certain License Agreement dated October 27, 2020, as amended by the First Amendment entered into as of January 28, 2022. The field of the license of LP659 is expanded to cover, in addition to the indications in the original field licensed to us, all therapeutic, prophylactic, and diagnostic uses in humans for any developmental, degenerative or autoimmune disease, disorder or condition of the central nervous system or peripheral nervous system. The company are providing Arena a right of first negotiation, for a specified period of time following the date of the Second Amendment, to acquire certain development and commercial rights to LP659 products subject to Arena and they mutually agreeing on terms. This right of first negotiation is triggered by their announcing Phase 2 clinical results relating to an LP659 product for an indication that was not in the original field of the license or if they otherwise intend to commence discussions or negotiations to license or partner rights to LP659 in such field.